Ewa Mrozek, MD
Medical Oncology · London, OHNPI 1972518314
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $503 of the $654 with a category attached, or 76.9%. It is spread thinly across 17 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.
Across 33 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$128
- Amgen$114
- Jazz Pharmaceuticals Inc.$58
- AstraZeneca$52
- Gilead$40
- Eisai Inc.$39
- plus $224 from 11 others
Across 1 payment — averaging $70,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$71K
What the payments were for
- Food & beverage$50377%
- Education$15123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 2 | $128 |
| Amgen | 9 | $114 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| AstraZeneca | 2 | $52 |
| Gilead | 2 | $40 |
| Eisai Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Acceleron Pharma, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Sanofi | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Pharmaand GmbH | 1 | $16 |
| Merck | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Pfizer | 1 | $14 |
How this compares
$654 in reported general payments places this provider in the 30th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 30 | $613 |
| Anastrozole | 28 | $395 |
| Dexamethasone | 14 | $248 |
| Ondansetron OdtOndansetron | 15 | $199 |
| Prochlorperazine Maleate | 16 | $191 |
| Hydroxyurea | 17 | $179 |
| Levothyroxine Sodium | 15 | $100 |
| Oxycodone Hcl | 17 | $97 |
| Tramadol Hcl | 16 | $66 |
| Prednisone | 21 | $52 |
| Lorazepam | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in London
- David CarboneColumbus$438K
- Elyse LowerCincinnati$312K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
- Mark MarinellaKettering$84K
- Timothy BurnsColumbus$64K
- William TseCleveland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.